Scorpion Therapeutics
One Winthrop Square
Suite 400
Boston
MA
02110
United States
Tel: 5086151886
30 articles about Scorpion Therapeutics
-
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
1/4/2024
Scorpion Therapeutics, Inc. announced leadership changes intended to position the Company for its next phase of growth, including the appointment of Adam Friedman, M.D., Ph.D., as Chief Executive Officer.
-
Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor
10/24/2023
Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.
-
Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023
10/13/2023
Scorpion Therapeutics, Inc announced preclinical data for STX-241, an orally bioavailable, highly selective, central nervous system -penetrant and potentially best-in-class fourth generation epidermal growth factor receptor tyrosine kinase inhibitor designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation in non-small cell lung cancer.
-
Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
10/10/2023
Scorpion Therapeutics, Inc. and Pierre Fabre Laboratories announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-721, Scorpion's highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting epidermal growth factor receptor and ERBB2 Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.
-
Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors
5/2/2023
Scorpion Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-478.
-
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer
4/4/2023
Scorpion Therapeutics, Inc. (“Scorpion”) today announced an exclusive collaboration and license agreement for the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor ("EGFR") inhibitors.
-
Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer
4/3/2023
Scorpion Therapeutics, Inc. (“Scorpion”), a clinical-stage biotechnology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it has named STX-241 as its next development candidate.
-
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
12/8/2022
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3K α Inhibitor at San Antonio Breast Cancer Symposium.
-
Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
11/21/2022
Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it will present preclinical data on STX-478, its potential best-in-class mutant-selective PI3Kα inhibitor, in a poster session at San Antonio Breast Cancer Symposium (“SABCS”) in San Antonio, Texas, taking place December 6 – 10, 2022.
-
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board
11/7/2022
Scorpion Therapeutics, Inc., a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, announced the formation of its Clinical Scientific Advisory Board.
-
Scorpion Therapeutics is on a mission to create a world where many more cancer patients can benefit from precision therapies. Earlier this year, it struck a $75 million alliance with AstraZeneca.
-
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022
10/26/2022
Scorpion Therapeutics, Inc. announced preclinical proof-of-concept data for STX-721, the Company’s first development candidate from its STX-EGFR-EXON-20 program. STX-721 is a next-generation, orally delivered therapy, designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors, a well-known, clinically validated oncogenic driver in non-small cell lung cancer.
-
Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium
10/12/2022
Scorpion Therapeutics, Inc. today announced that it will present preclinical proof-of-concept data for STX-721 in a poster session at the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research Symposium 2022 in Barcelona, Spain, taking place October 26 – 28, 2022.
-
Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022
9/12/2022
Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
-
Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer
9/12/2022
Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine, today announced the appointment of Michael Streit, M.D., M.B.A as the Company’s first Chief Medical Officer (“CMO”).
-
Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile
6/29/2022
STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents.
-
Scorpion Therapeutics to Present at Jefferies Healthcare Conference
6/3/2022
Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in New York City.
-
Scorpion Therapeutics Announces Discovery Scientific Advisory Board
6/2/2022
Members include pioneers of cancer biology and computational biology who have discovered key drivers of the disease and advanced the discovery of new therapies.
-
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022
4/8/2022
Scorpion Therapeutics, Inc. today announced preclinical proof-of-concept data for STX-478.
-
Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors
4/4/2022
Scorpion Therapeutics, Inc. today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors.